FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048469892> ?p ?o ?g. }

• W2048469892 endingPage "S14" @default.
• W2048469892 startingPage "S8" @default.
• W2048469892 abstract "Pain affects most patients with malignant disease, and the prevalence of severe pain increases in the advanced stages of the condition. One in 5 patients with cancer has uncontrolled pain, even after 10 years of the use of the World Health Organization programme for cancer pain control and its ‘three-step ladder’ for the rational use of analgesics including morphine. Morphine has long been the ‘gold standard’ for the treatment of severe cancer pain. However, its side-effects, particularly sedation, cognitive impairment and myoclonus at high doses, have provoked the use of ‘opioid rotation’ to alternatives such as methadone and hydromorphone. The new 72-h transdermal patch for fentanyl also offers advantages of reduced side-effects and increased convenience over oral morphine. Intravenous strontium-89 and bisphosphonate therapy are effective for both short- and long-term control of metastatic bone pain. The spinal N-methyl-d-aspartate (NMDA) receptor is important in modulating the plasticity of the central nervous system and in aggravating chronic pain through the phenomenon of ‘wind-up’. The NMDA antagonist ketamine, an anaesthetic, can be used at low doses for the management of refractory and neuropathic pains. Among adjuvant drugs, ketorolac has emerged as a potent non-steroidal anti-inflammatory drug. Palliative care is gaining acceptance as a new discipline in healthcare. Its strategic role is being reviewed as an adjunct to cancer therapy at all stages and its use is no longer confined to the terminal phase of disease after curative treatment has failed. Pain control and other aspects of symptom control are, therefore, viewed as an integral part of cancer management. Pain affects most patients with malignant disease, and the prevalence of severe pain increases in the advanced stages of the condition. One in 5 patients with cancer has uncontrolled pain, even after 10 years of the use of the World Health Organization programme for cancer pain control and its ‘three-step ladder’ for the rational use of analgesics including morphine. Morphine has long been the ‘gold standard’ for the treatment of severe cancer pain. However, its side-effects, particularly sedation, cognitive impairment and myoclonus at high doses, have provoked the use of ‘opioid rotation’ to alternatives such as methadone and hydromorphone. The new 72-h transdermal patch for fentanyl also offers advantages of reduced side-effects and increased convenience over oral morphine. Intravenous strontium-89 and bisphosphonate therapy are effective for both short- and long-term control of metastatic bone pain. The spinal N-methyl-d-aspartate (NMDA) receptor is important in modulating the plasticity of the central nervous system and in aggravating chronic pain through the phenomenon of ‘wind-up’. The NMDA antagonist ketamine, an anaesthetic, can be used at low doses for the management of refractory and neuropathic pains. Among adjuvant drugs, ketorolac has emerged as a potent non-steroidal anti-inflammatory drug. Palliative care is gaining acceptance as a new discipline in healthcare. Its strategic role is being reviewed as an adjunct to cancer therapy at all stages and its use is no longer confined to the terminal phase of disease after curative treatment has failed. Pain control and other aspects of symptom control are, therefore, viewed as an integral part of cancer management." @default.
• W2048469892 created "2016-06-24" @default.
• W2048469892 creator A5081991608 @default.
• W2048469892 date "1997-07-01" @default.
• W2048469892 modified "2023-10-10" @default.
• W2048469892 title "New approaches to pain control in patients with cancer" @default.
• W2048469892 cites W1972448628 @default.
• W2048469892 cites W1978186688 @default.
• W2048469892 cites W1978989391 @default.
• W2048469892 cites W1988201987 @default.
• W2048469892 cites W1988764641 @default.
• W2048469892 cites W2045051119 @default.
• W2048469892 cites W2058401615 @default.
• W2048469892 cites W2059867560 @default.
• W2048469892 cites W2074488518 @default.
• W2048469892 cites W2075464999 @default.
• W2048469892 cites W2081887464 @default.
• W2048469892 cites W2082986563 @default.
• W2048469892 cites W2090911754 @default.
• W2048469892 cites W2093371287 @default.
• W2048469892 cites W2094180609 @default.
• W2048469892 cites W2100514946 @default.
• W2048469892 cites W2113250961 @default.
• W2048469892 cites W2146263498 @default.
• W2048469892 cites W2317029808 @default.
• W2048469892 cites W2461162930 @default.
• W2048469892 cites W2461762219 @default.
• W2048469892 cites W2468600832 @default.
• W2048469892 cites W2473405326 @default.
• W2048469892 cites W4231599650 @default.
• W2048469892 cites W4233080790 @default.
• W2048469892 cites W4248582035 @default.
• W2048469892 doi "https://doi.org/10.1016/s0959-8049(97)00205-0" @default.
• W2048469892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9404234" @default.
• W2048469892 hasPublicationYear "1997" @default.
• W2048469892 type Work @default.
• W2048469892 sameAs 2048469892 @default.
• W2048469892 citedByCount "62" @default.
• W2048469892 countsByYear W20484698922012 @default.
• W2048469892 countsByYear W20484698922013 @default.
• W2048469892 countsByYear W20484698922014 @default.
• W2048469892 countsByYear W20484698922015 @default.
• W2048469892 countsByYear W20484698922016 @default.
• W2048469892 countsByYear W20484698922017 @default.
• W2048469892 countsByYear W20484698922019 @default.
• W2048469892 countsByYear W20484698922020 @default.
• W2048469892 crossrefType "journal-article" @default.
• W2048469892 hasAuthorship W2048469892A5081991608 @default.
• W2048469892 hasConcept C121608353 @default.
• W2048469892 hasConcept C126322002 @default.
• W2048469892 hasConcept C142724271 @default.
• W2048469892 hasConcept C159110408 @default.
• W2048469892 hasConcept C170493617 @default.
• W2048469892 hasConcept C1862650 @default.
• W2048469892 hasConcept C204787440 @default.
• W2048469892 hasConcept C2776608144 @default.
• W2048469892 hasConcept C2777107010 @default.
• W2048469892 hasConcept C2777389121 @default.
• W2048469892 hasConcept C2778904085 @default.
• W2048469892 hasConcept C2779158186 @default.
• W2048469892 hasConcept C2780795376 @default.
• W2048469892 hasConcept C2781063702 @default.
• W2048469892 hasConcept C2781118164 @default.
• W2048469892 hasConcept C2994186709 @default.
• W2048469892 hasConcept C42219234 @default.
• W2048469892 hasConcept C55932262 @default.
• W2048469892 hasConcept C71924100 @default.
• W2048469892 hasConceptScore W2048469892C121608353 @default.
• W2048469892 hasConceptScore W2048469892C126322002 @default.
• W2048469892 hasConceptScore W2048469892C142724271 @default.
• W2048469892 hasConceptScore W2048469892C159110408 @default.
• W2048469892 hasConceptScore W2048469892C170493617 @default.
• W2048469892 hasConceptScore W2048469892C1862650 @default.
• W2048469892 hasConceptScore W2048469892C204787440 @default.
• W2048469892 hasConceptScore W2048469892C2776608144 @default.
• W2048469892 hasConceptScore W2048469892C2777107010 @default.
• W2048469892 hasConceptScore W2048469892C2777389121 @default.
• W2048469892 hasConceptScore W2048469892C2778904085 @default.
• W2048469892 hasConceptScore W2048469892C2779158186 @default.
• W2048469892 hasConceptScore W2048469892C2780795376 @default.
• W2048469892 hasConceptScore W2048469892C2781063702 @default.
• W2048469892 hasConceptScore W2048469892C2781118164 @default.
• W2048469892 hasConceptScore W2048469892C2994186709 @default.
• W2048469892 hasConceptScore W2048469892C42219234 @default.
• W2048469892 hasConceptScore W2048469892C55932262 @default.
• W2048469892 hasConceptScore W2048469892C71924100 @default.
• W2048469892 hasLocation W20484698921 @default.
• W2048469892 hasLocation W20484698922 @default.
• W2048469892 hasOpenAccess W2048469892 @default.
• W2048469892 hasPrimaryLocation W20484698921 @default.
• W2048469892 hasRelatedWork W1553735151 @default.
• W2048469892 hasRelatedWork W1826791800 @default.
• W2048469892 hasRelatedWork W1933185322 @default.
• W2048469892 hasRelatedWork W1965804297 @default.
• W2048469892 hasRelatedWork W2005348543 @default.
• W2048469892 hasRelatedWork W2055091785 @default.
• W2048469892 hasRelatedWork W2088345020 @default.
• W2048469892 hasRelatedWork W2161976818 @default.

• next